IL33 and gastric cancer: In gastric cancer, CAF-derived IL-33 enhances the migration and invasion of gastric cancer cells by inducing the epithelial–mesenchymal transition (EMT), and the secretion of IL-33 by CAFs is dependent on the activation of the TNFR2-NF-κB-IRF1 pathway (88).